Caris Life Sciences

Caris Life Sciences is a precision medicine and AI-driven TechBio company founded in 2008, headquartered in Phoenix, Arizona. The company specializes in molecular profiling and oncology diagnostics, operating a CLIA-certified laboratory that has processed over 1 million cases and 6.5 million tests. Caris develops comprehensive genomic and transcriptomic assays combining whole exome sequencing (WES), whole transcriptome sequencing (WTS), and protein analysis across 23,000+ genes. The company offers two primary clinical offerings: Caris Assure, a blood-based liquid biopsy utilizing circulating nucleic acid sequencing (cNAS) for pan-cancer profiling, and Caris MI Profile, a tissue-based assay delivering DNA, RNA, and protein analysis with AI-predictive algorithms. Caris maintains one of the largest multimodal databases globally—over 740,000 matched molecular and clinical outcomes records—which powers its proprietary Molecular AI platform. This AI engine generates 220+ interpretations and has measured over 50 billion molecular markers. The company serves oncologists, cancer patients, and biopharma partners across the care continuum: disease detection, therapy selection, and treatment monitoring. Caris publishes extensively (1,200+ peer-reviewed publications) and maintains partnerships with 45+ NCI-Designated Cancer Centers and 95+ members worldwide. The platform enables personalized, precision-oncology treatment decisions by revealing molecular blueprints and predicting individual patient response to therapies.